Related Experiment Videos
Autoimmune reactions in patients with silicone breast implants
J Zazgornik1, H Piza, W Kaiser
1II. Department of Medicine, General Hospital Linz.
Wiener Klinische Wochenschrift
|December 27, 1996
Summary
Women with silicone breast implants showed higher rates of autoantibodies, particularly antinuclear antibodies (ANA), compared to controls. While autoantibodies were detected, no participants met criteria for connective tissue disease.
Area of Science:
- Immunology
- Rheumatology
- Plastic Surgery
Background:
- Silicone breast implants are common surgical devices with a history spanning over three decades.
- Previous reports suggest a potential link between silicone augmentation and immune-related diseases, though such associations are rare.
Purpose of the Study:
- To investigate the prevalence of autoimmune reactions in women with silicone breast implants.
- To compare immunological markers between women with implants and a matched control group.
Main Methods:
- A retrospective single-center study involving 36 women with silicone breast implants and 36 controls.
- Evaluation of autoimmune markers including antinuclear antibodies (ANA), rheumatoid factor (RF), and thyroid antibodies (TMS).
- Assessment of other immunological parameters such as angiotensin-converting enzyme (ACE) and C-reactive protein (CRP).
Main Results:
- A significantly higher percentage of women with silicone implants (33%) had elevated ANA titers compared to controls (8%; p < 0.02).
- Overall, 39% of women with implants showed detectable autoantibodies, including ANA, antismooth muscle antibodies (ASMA), antineutrophilic cytoplasm antibodies (ANCA), and thyroid antibodies.
- Only one patient with implants reported musculoskeletal symptoms; however, none met the ARA criteria for connective tissue disease.
Conclusions:
- Silicone breast augmentation is associated with a higher prevalence of autoantibodies, predominantly organ-unspecific types like ANA.
- The detected autoantibodies in women with implants did not correlate with specific clinical entities or connective tissue diseases based on ARA criteria.